Connect with us

Cannabis

Flora Constructing EU-GMP Compliant Facilities Through Breeze Laboratory

GlobeNewswire

Published

on

TORONTO, July 15, 2020 (GLOBE NEWSWIRE) — Flora Growth Corp. (“Flora” or the “Company”) is pleased to provide a corporate update on the facilities expansion for Breeze Laboratory S.A.S. (“Breeze”). Since announcing the intent to acquire Breeze in April 2020, Flora has helped initiate several expansion projects to improve Breeze’s manufacturing capabilities to better serve Flora’s brand portfolio.
“Once the acquisition of Breeze is complete, it will be the newest member of the Flora portfolio, and one of the most important, as it will act as the manufacturing hub for our products,” commented Flora’s CEO, Damian Lopez. “Breeze’s ongoing facilities expansion is an important step in growing Flora’s business, and we are excited to provide investors with a full update on the progress so they may better appreciate its significance.”About Breeze’s Facilities ExpansionIn order to meet Flora’s market-expansion targets, Breeze is constructing new facilities that are intended to meet international standards to obtain quality certifications including Good Laboratory Practices, BPE, EU-GMP, and Cosmetics-GMP. These facilities are projected to be used to manufacture products for Mambe, Flora Beauty, and Cronomed using the organic CBD oil produced at Cosechemos.BPE & EU-GMP FacilityA new 6,500 sq. ft. BPE and EU-GMP-compliant manufacturing facility is approximately 30% constructed, with completion forecasted for November 2020. The certification processes will be initiated once construction is complete and approvals are expected as early as February 2021.The new facility will be divided into three segments for different products: sterile master medicines, non-sterile master medicines, and cannabis master medicines. We believe that the BPE and EU-GMP certifications will ensure we adhere to current best-practices for enhancing product purity and safety and are able to export our products globally.Cosmetics-GMP FacilityA second new 10,500 sq. ft. cosmetics-GMP manufacturing facility is approximately 30% constructed, with completion forecasted for October 2020. The certification process will be initiated once construction is complete and approvals are expected as early as January 2021.The new facility is intended to be used for manufacturing Flora Beauty’s line of cannabis and non-cannabis cosmetics. We believe that the cosmetics-GMP certification will ensure product quality and global export capabilities for Flora Beauty’s entire line of products.Update on Breeze’s KEEP CLEAN Coronavirus Prevention KitsBreeze continues to manufacture and sell its KEEP CLEAN coronavirus prevention kits across Colombia through e-commerce (keepclean.com.co) and traditional channels, and on Rappi, South America’s largest on-demand consumer delivery service.Breeze is marketing the kits through assorted partnerships, including with the Esteban Chaves Foundation, and helping educate the broader public about the importance and necessity of taking steps to prevent the spread of the coronavirus. The kits have also received approval for import in the United States, where Breeze intends on selling the kits through e-commerce channels.About Breeze Laboratory S.A.S.Breeze is a cosmetic and dermo-cosmetic development and manufacturing company based in Bogota, Colombia. The company currently manufactures INVIMA (Colombian FDA-equivalent) approved cosmetics and dermo-cosmetics and has started the process of building EU-GMP compliant facilities.Earlier this year, Flora announced the signing of a letter of intent to acquire a 90% stake in Breeze (the “Transaction”). Completion of The Transaction remains subject to the parties negotiating and entering into a definitive agreement and is expected after the current Regulation A+ Tier 2 offering closes.Flora Growth Corp.Flora is a vertically integrated cannabis company striving to be a globally recognized cannabis brand by leveraging low-cost production of cannabis to supply CBD oil to our portfolio of consumer and medical brands.For further information, contact:
Evan Veryard
Vice President Investor Relations
+1 416 571 9037
evan.veryard@floragrowth.ca
Website: www.floragrowth.ca
Cautionary Notes  
This news release may contain forward-looking statements. These statements include statements regarding the Company’s operations, Breeze’s operations, the Company’s ability to close the Transaction, the construction and anticipated time to completion of, and BPE, EU-GMP, and Cosmetics-GMP certification processes respecting, the manufacturing facilities, the Company’s and Breeze’s ability to obtain regulatory approvals to infuse medicinal cannabis into products and the Company’s future plans and objectives. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially. We do not assume any obligation to update any forward-looking statements, except as required by applicable laws.

Cannabis

Successful completion of feasibility study for the development of topical medical cannabis products based on AKVANO® technology

Vlad Poptamas

Published

on

 

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions.

Product development of such topical medical Cannabis products based on AKVANO® is being conducted under a collaboration between Cannassure and Lipidor AB (“Lipidor”), a Swedish topical drug development company, owner of the proprietary drug delivery platform technology AKVANO, which was signed in December 2019. The development project budget is partially funded by the Israeli Innovation Authority, by a non-dilutive grant.

The product under development is an incorporation of cannabinoids with AKVANO®, a topical drug delivery platform. Successful development of the product will allow localized administration of a precise dosage of cannabinoids using a spray, in a technology that allows for prolonged contact and optimal penetration of the active ingredient into the skin.

As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, and it was found that the cannabinoids can be successfully combined in the AKVANO® system for a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin by using known and acceptable models and found significant penetration of active ingredients into the skin tissue. This enhanced penetration may increase the therapeutic potential of the product. Based on these results, Cannassure will proceed to accelerated development stages and more advanced testings.

According to the agreement, Cannassure has informed Lipidor on its intention to start negotiating an exclusive global license for the use of Lipidor’s technology for the development of cannabinoids based topical therapeutics products for the treatment of indications to be chosen by Cannassure.

The main guidelines for the licencing agreement, including royalties to be paid to Lipidor on product sales, were defined in the collaboration agreement.

According to estimates, the global market for products for the treatment of psoriasis is expected to reach 21.1 billion dollars by 20221. The current global market for topical products for the treatment of psoriasis is valued at 7 billion dollars2, and the global market for topical pain treatment products is projected to reach 13 billion dollars3.

The product development of topical treatments based on cannabinoids is in line with Cannassure’s strategy focused on the development and commercialisation of innovative medical cannabis products based on established drug delivery systems and formulations for enhanced therapeutic value. The product development is performed under the Israeli Medical Cannabis regulation, which allows a short development process.

Continue Reading

Cannabis

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company’s AKVANO® technology

Vlad Poptamas

Published

on

Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. , an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the joint development agreement signed in December 2019, Cannassure has now announced that it intends to exercise its option and begin the negotiation of an exclusive licensing agreement for the use of AKVANO®, Lipidor’s proprietary drug delivery technology, for the indications chosen by Cannassure. The main guidelines for the licencing agreement, including royalties (double digit) to be paid to Lipidor on product sales, were defined in the collaboration agreement.

The collaboration began with an evaluation of the possibility of incorporating various active drug substances from the cannabis plant into AKVANO®. The formulation work has been carried out in Israel at Cannassure’s state-of-the-art facilities with support from Lipidor’s formulation experts.

The product under development is based on a topical medical cannabinoid that has been incorporated into the AKVANO® formulation platform. The successful development of the product will make it possible to administer the medical cannabinoid as a spray, locally and in the exact desired amount, which together ensures improved contact and optimal penetration of the active substance into the skin.

As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, demonstrating that cannabinoids can be combined in the AKVANO® system as a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin using known and accepted models and found significant penetration of active ingredients into skin tissue. This improved penetration may increase the therapeutic potential of the product. According to Cannassure, based on these results, the company will go ahead, accelerating the pace of development steps and conducting more advanced testing. Cannassure will implement the technology for the development and commercialization of sprayable medicinal cannabis products based on AKVANO®.

The common goal is to introduce innovative topical treatments to the fast-growing global market for medical cannabis products.

“We are very pleased with the positive outcome of the feasibility study, which confirms our previous high hopes. The result is an important milestone for Lipidor and for our unique formulation platform, showing that cannabinoids can be incorporated into AKVANO®. The collaboration with our partner Cannassure represents significant commercial potential for Lipidor,” says Ola Holmlund, CEO of Lipidor AB.

“We look forward to continued successful cooperation with Cannassure in the field of medical cannabis.”

This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-09-2020 08:00 CET.

Continue Reading

Cannabis

Christina Lake Announces Commencement of Trading on the CSE

GlobeNewswire

Published

on

VANCOUVER, British Columbia, Sept. 29, 2020 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”), a premier producer of high-quality, low-cost, sun-grown cannabis flower, oil cannabinoids, as well as hemp-based extracts and derivatives, serving domestic and international markets, is pleased to announce that its common shares will begin trading on the Canadian Securities Exchange (“CSE”) at 9:30 am EDT on Thursday October 1, 2020 under the ticker symbol “CLC”.

In October 2018, CLC began its roadmap to becoming one of the largest firms in the country for outdoor cannabis cultivation and extraction by purchasing a cultivation building and fully-serviced 32-acre site in the Christina Lake region of British Columbia. CLC received approval for a standard cultivation license from Health Canada in early 2019, with a research and development license granted in the beginning of 2020. In summer 2020 the Company began harvesting more than 22,500 plants of eight unique cannabis strains, which is expected to yield a minimum of 22,500 kg/49,500 lb. With over 30 full-time staff members and seasonal workers, CLC is also the largest employer in its region. To date, the Company’s successive investment rounds have raised a total of approximately CAD $16,000,000, which enables CLC to maintain a reserve of funds for ongoing operations.

Nicco Dehaan, a founder of the Company and its Chief Operating Officer commented, “Having been part of CLC from the beginning, I am very proud of the progress made since 2018 for both the Company and the cannabis industry in general. We were very confident in the amount of growth potential this industry had, and we knew Christina Lake would be the perfect region in which to conduct outdoor growing of cannabis. As with any regulated industry, there were many hoops to jump through in order to obtain license approvals and build out a compliant operating structure. Further, applying to have CLC’s equity traded on a public stock exchange introduces a whole other set of requirements to meet and satisfy on an ongoing basis. Between obtaining our licensed producer status from Health Canada, hiring on full-time personnel for several key professional roles, and beginning to harvest our first crop for the 2020 growing season, receiving approval for trading on the CSE is an excellent addition to our momentum as we prepare to bring our first crop to market. We look forward to a productive Q4 2020, with very exciting developments to be had in 2021 and beyond.”

About Christina Lake Cannabis Corp.

Christina Lake Cannabis Corp is a Licensed Producer of cannabis under the Cannabis Act which also received a Research and Development License from Health Canada on May 20, 2020. CLC’s facility is comprised of a 32-acre property, which includes over 950,000 square feet of outdoor grow space, offices, propagation and drying rooms, as well as research facilities, and a facility dedicated to processing and extraction. CLC cultivates cannabis using strains specifically developed for outdoor cultivation and expects to produce 22,500 kg or more from its 32-acre facility before developing its adjacent 99-acre expansion property, which will bring its cultivation footprint to over 4.35 million square feet or over 88,000 kg of low-cost, high-quality, sun-grown cannabis annually.

For more information about CLC, please visit: www.clcannabis.com

On behalf of Christina Lake Cannabis Corp.:

“Joel Dumaresq”

Joel Dumaresq, CEO and Director

Jamie Frawley
Investor Relations
jamie@clcannabis.com
416-268-9432

Robyn Rabinovich
Media Inquiries
robyn.rabinovich@hkstrategies.ca
416-413-4775

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania